WALKOUT
9.12.2021 18:55:13 CET | Business Wire | Press release
The Israeli company WalkOut , the developer of an autonomous end-to-end frictionless shopping solution, announces an extensive cooperation agreement with Machsanei Hashuk , one of the largest supermarket chains in Israel. As part of the agreement, the chain will implement the fully autonomous checkout solution, considered the most accurate in the world's retail industry, in all 62 of its branches. Its deployment will begin as early as next month.
Although 61 percent of shoppers would prefer to purchase brands that also have a physical location, over 70 percent of shoppers report that standing in line for checkouts is frustrating and detracts from the shopping experience. Until the development of WalkOut’s solution, no system has accompanied the customer throughout the entire purchase, which includes actual checkout.
WalkOut’s retrofit smartcart solution offers a revolution in the shopping experience that addresses two main challenges that marketing chains face in the physical buying process.
The first is related to waiting in long queues at the checkout. The second is the inability to create a personalized shopping experience for each customer.
The company’s first-ever truly seamless retrofitted solution in the retail industry requires no costly infrastructural changes to the store, while other solutions require the retailer to purchase new carts and most rely on barcode scanners and scales for item recognition. The mountable cart device's multiple high-precision cameras, which utilize many different proprietary algorithms to accurately recognize products, identify the items as shoppers load or remove them with 99.2 percent accuracy.
WalkOut’s edge computing and machine-vision algorithms also curtail the need for costly on-cloud servers and high-bandwidth internet support. This use of single-sensor architecture and edge-computing allows retail stores to operate a much more robust and cost-effective solution. Through a large touchscreen, the device also communicates with the customer to offer personalized recommendations, store navigation, supplementary product information, and relevant promotions based on the shopper's history and location in the store.
"Connecting to one of the largest retail chains in Israel is an exciting opportunity and an important milestone for us," says Assaf Gedalia, CEO and Co-Founder of WalkOut. “The solution is futuristic, personalized, and at the same time preserves the customer's privacy."
"As a chain that advocates innovative technologies, we wanted to offer our customers significant savings in waiting times at the checkouts and provide a more personal, accessible and efficient shopping experience," said Shalom Naaman, CEO and Owner of Machsanei Hashuk. "The WalkOut solution will significantly shorten the length of stay in the branches, help maximize our operational efficiency, and allow us to offer one of the most advanced shopping experiences in the world."
About WalkOut
WalkOut
, founded in 2018, has set itself the goal of changing the way consumers purchase products in physical stores by placing the checkout directly on the shopping cart. The company's solution is based on machine vision technology capable of identifying any item placed or removed from the cart and calculating it in the final payment. In this way, the cart eliminates the need for a checkout and reduces the duration of the payment process to a minimum. The WalkOut solution includes a large touch screen located on the cart and combines a personalized shopping experience with offers and promotions based on each consumer's preferences, complementary products and the location of the products in the store. The WalkOut system is modular and can be installed on existing carts in stores without the need for significant changes on the part of the store.
About Machsanei Hashuk
Machsanei Hashuk is a leading marketing chain owned and managed by the Naaman & Cohen families that was first established in 1996 in the city of Beer Sheva. The chain currently has 62 branches nationwide from Safed to Eilat. In 2019, the chain acquired Co-op, and in doing so became one of the largest leading marketing chains in Israel. Co-op branches have since been converted into "Machsanei Hashuk sheli''. The chain operates an advanced and accessible online site, in addition to its branches. It also offers its own Wincard+ credit card, in cooperation with Max, which combines regular card rewards with the chain's own promotions. Machsanei Hashuk operates a strong and active customer club with more than 400,000 loyal customers.
The chain is the official sponsor of the football team "Hapoel Machsanei Hashuk Beer-Sheva.” For more information, visit https://www.mck.co.il/
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005892/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
